Abiopharma

Helix BioPharma is a biopharmaceutical company specializing in the field of cancer therapy. The Company is developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helixs clinical product development initiatives include Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus. Helix is also developing its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma.

Additional info from SGX:

iX Biopharma Ltd is a specialty pharmaceutical and nutraceutical company, operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. iX Biopharma focus on the development and commercialisation of therapies for diseases of the central nervous system using its novel, patent-protected platform sublingual drug delivery technology, WaferiX. iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. Silcap is also approved in Singapore. iX Biopharma’s Xativa is the world’s first freeze-dried sublingual medicinal cannabis wafer. The Group’s nutraceuticals division, Entity Health Limited (Entity), is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through pharmacies and health food shops and in China and globally through its online e-commerce stores.

Additional info from OTC:
Helix BioPharma is a biopharmaceutical company specializing in the field of cancer therapy. The Company is developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helixs clinical product development initiatives include Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus. Helix is also developing its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma.